Contributions of StopperingSteff

User contributions·32 logged edits·page 1 of 1

Contributions by StopperingSteff, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 966 edits includes activity predating the current log.

13:08, 21 Jun 2026 (diff | hist) Chain of custody 5,157 ±0 add the turnaround time the service publishes
14:05, 20 May 2026 (diff | hist) Talk:Vial filling and stoppering 748 +85 /* Two-stage stoppering */ reply
14:20, 22 Apr 2026 (diff | hist) Talk:Underfilling 748 +125 /* Overage section balances the article */ reply
23:51, 15 Apr 2026 (diff | hist) Temperature excursion 24,964 ±0 give the closure integrity test by name
05:53, 10 Apr 2026 (diff | hist) Contract development and manufacturing organisation 5,011 ±0 fix hyphenation per PP:MOS
09:50, 24 Mar 2026 (diff | hist) Talk:Vial filling and stoppering 400 +140 /* Vacuum check */ new section
11:44, 21 Feb 2026 (diff | hist) PolyPeptide Group (Hangzhou) 17,422 +860 add the reception tally with its period and count stated
14:58, 6 Feb 2026 (diff | hist) Talk:Vial 1,022 +368 /* Polymer containers deserve more than a paragraph */ reply
23:30, 15 Sep 2025 (diff | hist) Contract development and manufacturing organisation 5,011 +217 fix the anchor on an internal link
23:24, 7 Sep 2025 (diff | hist) Temperature excursion 15,979 +1,808 consistent en dashes in ranges
21:12, 9 Aug 2025 (diff | hist) Resin cleavage 4,029 ±0 m clarify that the cake appearance is an indicator, not a specification
10:38, 2 Jul 2025 (diff | hist) Talk:Vial 1,170 +80 /* Overflow capacities in the R-series table */ reply
17:11, 30 Jun 2025 (diff | hist) Talk:Vial 748 +325 /* Overflow capacities in the R-series table */ reply
15:35, 17 Apr 2025 (diff | hist) Glucagon-like peptide-1 10,252 +13 attribute the gastric-emptying effect to the study that measured it
07:38, 12 Apr 2025 (diff | hist) Contract development and manufacturing organisation 3,804 ±0 rm the vendor-specific packaging detail; not general enough for the article
08:57, 2 Apr 2025 (diff | hist) Talk:Multi-dose vial 1,170 +250 /* Merge proposal from Vial — response */ reply
02:22, 30 Mar 2025 (diff | hist) Vial 18,279 +550 m add the reconstitution-stability sentence with its storage condition
09:33, 25 Mar 2025 (diff | hist) Talk:Multi-dose vial 537 +402 /* Merge proposal from Vial — response */ new section
23:22, 19 Mar 2025 (diff | hist) Repackaging 3,958 ±0 m add the excursion tolerance with the study it derives from
13:40, 18 Mar 2025 (diff | hist) Talk:Vial 611 +341 /* Merge proposal: Multi-dose vial into this article */ reply
02:40, 10 Feb 2025 (diff | hist) Cold-chain freight 3,111 +26 m clarify that "cold chain" without a logger is a claim, not a record
23:03, 30 Jan 2025 (diff | hist) Oral semaglutide 3,519 +278 attribute the potency comparison to the head-to-head trial rather than to two separate ones
00:47, 22 Jan 2025 (diff | hist) Vial filling and stoppering 3,355 +582 m state that a phase-change pack and a gel pack behave differently
05:45, 31 Dec 2024 (diff | hist) Fmoc chemistry 3,718 +206 m add category for logistics
11:43, 7 Oct 2024 (diff | hist) Timeline of incretin therapeutics 2,352 ±0 add the excipient list from the labelling
04:55, 6 Oct 2024 (diff | hist) Custom peptide synthesis 2,139 ±0 m fix a broken wikilink
20:44, 30 Sep 2024 (diff | hist) Solid-phase peptide synthesis 2,718 ±0 rm the shipping recommendation — that is advice, not description
02:22, 12 Sep 2024 (diff | hist) Dulaglutide 1,910 +1,910 N new article: compound, expansion welcome
21:00, 5 Sep 2024 (diff | hist) Resin cleavage 2,085 +407 add the collapse-temperature point, sourced
09:10, 5 Sep 2024 (diff | hist) Weight regain after discontinuation 1,201 +1,201 N new article: adverse effects, expansion welcome
14:03, 6 Aug 2024 (diff | hist) Wuhan Wansheng Biotechnology 4,317 +696 add the standing talk-page note link to the banner
03:02, 10 Jul 2024 (diff | hist) Peptide synthesis 2,036 ±0 m add category for logistics